AstraZeneca to buy Ardea Biosciences for £781m

The Independent reported that the British drug maker AstraZeneca has agreed a $1.26bn (£781m) deal to buy San Diego firm Ardea Biosciences.

AstraZeneca which is the UK 2nd biggest drug developer is currently looking for new products, acquiring Ardea also means that Astra Zeneca gains a drug called Lesinurad,

Ardea, California-based biotechnology company focused on the development of small-molecule therapeutics. Ardea’s top drug  Lesinurad  is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout. This disease is expected to affect almost 17 million people by 2019.

David Brennan, AstraZeneca’s chief executive, said: This attractive Phase III programme is an excellent opportunity to leverage AstraZeneca’s global specialty and primary care sales and marketing capabilities…..The Ardea team has done a great job developing Lesinurad along with a promising next-generation gout programme. These compounds have real potential to benefit patients.”

Click here to see our clinical roles in the UK and Europe

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in Industry News, NewsTagged in , , , , , , , , ,

Genzyme to Cut 1,000 Jobs by Selling Division

Scientific researchAs reported by the Boston Globe, the global biotechnology company Genzyme, plans to cut 1,000 jobs when it sells its genetics testing business to Laboratory Corp. of America in a deal worth $925 million.

The sale of the biotech’s genetics division marks a move by the company to expand into areas such as reproduction and onocology.

The move could also increase pressure on the company’s suitor Sanofi Aventis to buy the biotechnology company before it gets rid of anymore assets.

 

Are you looking for a new job in the biotechnology industry? Click here to search for our current biotech positions online now.

Posted in General, NewsTagged in , , , , , , ,